MILTON FINEGOLD to Cyclohexanones
This is a "connection" page, showing publications MILTON FINEGOLD has written about Cyclohexanones.
Connection Strength
0.430
-
Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. J Inherit Metab Dis. 1998 Aug; 21(5):518-31.
Score: 0.165
-
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet. 1995 Aug; 10(4):453-60.
Score: 0.134
-
Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology. 2008 Aug; 48(2):487-96.
Score: 0.021
-
Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008 Jul 08; 14(1):59-67.
Score: 0.021
-
Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. J Hepatol. 2008 Feb; 48(2):308-17.
Score: 0.020
-
Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment. Mol Genet Metab. 2008 Mar; 93(3):306-13.
Score: 0.020
-
Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. Biochem Pharmacol. 2006 May 28; 71(11):1648-61.
Score: 0.018
-
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology. 2004 Feb; 39(2):433-43.
Score: 0.015
-
Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. Hum Gene Ther. 1998 Feb 10; 9(3):295-304.
Score: 0.010
-
Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet. 1996 Mar; 12(3):266-73.
Score: 0.009